UC DIS.CERT. 12/24 BRM/ DE000HC8REB5 /
2024-11-12 9:46:02 PM | Chg.+0.680 | Bid9:57:32 PM | Ask2024-11-12 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
44.680EUR | +1.55% | 44.790 Bid Size: 6,000 |
- Ask Size: 6,000 |
BRISTOL-MYERS SQUIBB... | - - | 2024-12-31 | Call |
GlobeNewswire
09-02
CSE Announces its 2024 Sustainability & ESG Leadership Summit at NYC's One World Trade Center
GlobeNewswire
08-30
Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference
GlobeNewswire
08-28
Hematologists Highlight Ongoing Challenges in Sickle Cell Disease and Thalassemia Amidst Promising A...
GlobeNewswire
08-22
Abata Therapeutics Receives FDA Fast Track Designation for ABA-101 for the Treatment of Progressive ...
GlobeNewswire
08-15
Abata Therapeutics Announces Strategic Investment from Bristol Myers Squibb Supporting Advancement o...
GlobeNewswire
08-12
Altamira Therapeutics Announces Significant Enhancement of Immune Checkpoint Inhibition Therapy in C...
Newsfile Corp
08-12
The Cancer Battle - How Smaller Companies Are Making Big Advancements in Treatments for Solid Tumors
GlobeNewswire
08-08
CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
08-07
Efficacy and Safety Data of Sotagliflozin in Patients with Type 1 Diabetes and Chronic Kidney Diseas...
GlobeNewswire
08-05
iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer
GlobeNewswire
08-01
Outpace Bio Announces $144M Oversubscribed Series B Financing to Advance AI-powered Cell Therapies i...
GlobeNewswire
08-01
CytomX Therapeutics to Report Second Quarter 2024 Financial Results on August 8, 2024
GlobeNewswire
07-31
Mural Oncology Appoints Veteran Business Development Executive George Golumbeski, Ph.D., to its Boar...
GlobeNewswire
07-25
Purple Biotech Receives Extension to Regain Compliance with the Nasdaq’s Minimum Bid Price Rule
GlobeNewswire
07-24
Prota Therapeutics Strengthens Board with Appointment of Global Biotech Expert Patrick Machado
GlobeNewswire
07-20
NCLA Asks Third Circuit to Rule Against HHS’s Coercive Medicare Drug Price ‘Negotiation’ Program